Collegium Pharmaceutical Share Price (NASDAQ: COLL)

$38.81

▲

0.46

(1.2%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Collegium Pharmaceutical Stock chart to analyse performance

Collegium Pharmaceutical stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$38.25
Today's High:$38.82
$38.81
1.44%
Downside
Day's Volatility :1.46%
Upside
0.01%
52 Weeks Low:$23.23
52 Weeks High:$42.29
$38.81
40.14%
Downside
52 Weeks Volatility :45.07%
Upside
8.22%

Collegium Pharmaceutical Stock Returns

Period	Collegium Pharmaceutical Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	32.43%	3.6%	0.0%
6 Months	36.48%	-7.7%	0.0%
1 Year	3.73%	-12.6%	0.0%
3 Years	119.29%	9.5%	-4.7%

Collegium Pharmaceutical Inc Key Stats

Check Collegium Pharmaceutical key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$38.35
Open	$38.31
Today's High	$38.815
Today's Low	$38.25
Market Capitalization	$1.2B
Today's Volume	$520.6K
52 Week High	$42.2873
52 Week Low	$23.23
Revenue TTM	$707.0M
EBITDA	$375.8M
Earnings Per Share (EPS)	$1.06
PE Ratio	36.18
Profit Margin	5.13%
Quarterly Earnings Growth YOY	-0.34%
Return On Equity TTM	16.16%

Stock Returns calculator for Collegium Pharmaceutical Stock including INR - Dollar returns

The Collegium Pharmaceutical stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Collegium Pharmaceutical investment value today

Current value as on today

₹1,08,999

Returns

₹8,999

(+9%)

Returns from Collegium Pharmaceutical Stock

₹3,715 (+3.71%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Collegium Pharmaceutical Stock

33%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Collegium Pharmaceutical Stock from India on INDmoney has increased by 33% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Collegium Pharmaceutical Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
17.31%
Rubric Capital Management LP
10.02%
Eventide Asset Management, LLC
8.38%
Vanguard Group Inc
7.14%
Amvescap Plc.
5.18%
Renaissance Technologies Corp
5.13%

Analyst Recommendation on Collegium Pharmaceutical Stock

Rating

Trend

Buy

75%Buy

25%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Collegium Pharmaceutical(by analysts ranked 0 to 5 stars)

Collegium Pharmaceutical Share Price Target

What analysts predicted

Upside of 14.92%

Target:

$44.60

Current:

$38.81

Collegium Pharmaceutical share price target is $44.60, a slight Upside of 14.92% compared to current price of $38.81 as per analysts' prediction.

Collegium Pharmaceutical Stock Insights

Price Movement
In the last 1 month, COLL stock has moved up by 26.4%
Increasing Revenue
Revenue is up for the last 2 quarters, 177.75M → 188.0M (in $), with an average increase of 5.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 2.41M → 11.98M (in $), with an average increase of 79.8% per quarter
COLL vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 9.0%
Price to Sales
ForCOLL every $1 of sales, investors are willing to pay $1.8, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Collegium Pharmaceutical Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$296.7M	↑ 5.81%
Net Income	$-8.1M	↓ 79.18%
Net Profit Margin	-2.75%	↑ 11.2%

	FY20	Y/Y Change
Revenue	$310.0M	↑ 4.49%
Net Income	$26.8M	↓ 428.33%
Net Profit Margin	8.63%	↑ 11.38%

	FY21	Y/Y Change
Revenue	$276.9M	↓ 10.69%
Net Income	$71.5M	↑ 167.33%
Net Profit Margin	25.83%	↑ 17.2%

	FY22	Y/Y Change
Revenue	$463.9M	↑ 67.56%
Net Income	$-25.0M	↓ 134.96%
Net Profit Margin	-5.39%	↓ 31.22%

	FY23	Y/Y Change
Revenue	$566.8M	↑ 22.17%
Net Income	$48.2M	↓ 292.6%
Net Profit Margin	8.5%	↑ 13.89%

	FY24	Y/Y Change
Revenue	$631.4M	↑ 11.41%
Net Income	$69.2M	↑ 43.68%
Net Profit Margin	10.96%	↑ 2.46%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$144.9M	↓ 3.22%
Net Income	$27.7M	↓ 13.23%
Net Profit Margin	19.12%	↓ 2.21%

	Q2 FY24	Q/Q Change
Revenue	$145.3M	↑ 0.24%
Net Income	$19.6M	↓ 29.25%
Net Profit Margin	13.5%	↓ 5.62%

	Q3 FY24	Q/Q Change
Revenue	$159.3M	↑ 9.65%
Net Income	$9.3M	↓ 52.39%
Net Profit Margin	5.86%	↓ 7.64%

	Q4 FY24	Q/Q Change
Revenue	$181.9M	↑ 14.22%
Net Income	$12.5M	↑ 34.29%
Net Profit Margin	6.89%	↑ 1.03%

	Q1 FY25	Q/Q Change
Revenue	$177.8M	↓ 2.3%
Net Income	$2.4M	↓ 80.72%
Net Profit Margin	1.36%	↓ 5.53%

	Q2 FY25	Q/Q Change
Revenue	$188.0M	↑ 5.76%
Net Income	$12.0M	↑ 395.78%
Net Profit Margin	6.37%	↑ 5.01%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$103.0M	↓ 10.19%

	FY20	Y/Y Change
Profit	$179.8M	↑ 74.53%

	FY21	Y/Y Change
Profit	$150.6M	↓ 16.25%

	FY22	Y/Y Change
Profit	$209.5M	↑ 39.09%

	FY23	Y/Y Change
Profit	$326.2M	↑ 55.7%

	FY24	Y/Y Change
Profit	$377.3M	↑ 15.69%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$91.5M	↓ 3.35%

	Q2 FY24	Q/Q Change
Profit	$90.8M	↓ 0.71%

	Q3 FY24	Q/Q Change
Profit	$96.8M	↑ 6.59%

	Q4 FY24	Q/Q Change
Profit	$98.3M	↑ 1.54%

	Q1 FY25	Q/Q Change
Profit	$97.3M	↓ 0.98%

	Q2 FY25	Q/Q Change
Profit	$108.4M	↑ 11.36%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$27.8M	↓ 83.6%
Investing Cash Flow	$-6.4M	↓ 73.56%
Financing Cash Flow	$2.0M	↓ 101.74%

	FY20	Y/Y Change
Operating Cash Flow	$93.9M	↑ 238.13%
Investing Cash Flow	$-373.8M	↑ 5705.72%
Financing Cash Flow	$286.5M	↑ 13935.96%

	FY21	Y/Y Change
Operating Cash Flow	$103.6M	↑ 10.24%
Investing Cash Flow	$-1.9M	↓ 99.48%
Financing Cash Flow	$-89.3M	↓ 131.17%

	FY22	Y/Y Change
Operating Cash Flow	$124.2M	↑ 19.96%
Investing Cash Flow	$-573.7M	↑ 29410.85%
Financing Cash Flow	$436.7M	↓ 589.04%

	FY23	Y/Y Change
Operating Cash Flow	$274.7M	↑ 121.16%
Investing Cash Flow	$-70.8M	↓ 87.66%
Financing Cash Flow	$-140.2M	↓ 132.1%

	FY24	Y/Y Change
Operating Cash Flow	$205.0M	↓ 25.39%
Investing Cash Flow	$-287.8M	↑ 306.37%
Financing Cash Flow	$-60.6M	↓ 56.77%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$61.9M	↓ 15.55%
Investing Cash Flow	$-18.1M	↓ 27.77%
Financing Cash Flow	$-54.1M	↓ 20.17%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$67.4M	↑ 8.82%
Investing Cash Flow	$-8.9M	↓ 50.87%
Financing Cash Flow	$-114.2M	↑ 110.93%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-9.0M	↓ 113.35%
Investing Cash Flow	$-249.0M	↑ 2695.45%
Financing Cash Flow	$149.0M	↓ 230.49%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$84.6M	↓ 1040.59%
Investing Cash Flow	$-11.8M	↓ 95.28%
Financing Cash Flow	$-41.3M	↓ 127.7%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$55.4M	↓ 34.55%
Investing Cash Flow	$-9.7M	↓ 17.7%
Financing Cash Flow	$-25.2M	↓ 38.86%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$72.4M	↑ 30.76%
Investing Cash Flow	$-2.9M	↓ 69.89%
Financing Cash Flow	$-48.4M	↑ 91.67%

Collegium Pharmaceutical Technicals Summary

Sell

Neutral

Buy

Collegium Pharmaceutical is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Collegium Pharmaceutical Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Collegium Pharmaceutical Inc	29.99%	36.48%	3.73%	119.29%	107.46%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Collegium Pharmaceutical Inc	36.18	36.18	0.0	7.79	0.16	0.08	NA	7.36
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Collegium Pharmaceutical Inc	Buy	$1.2B	107.46%	36.18	5.13%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Organization	Collegium Pharmaceutical
Employees	357
CEO	Mr. Vikram Karnani
Industry	Health Technology

Key Management of Collegium Pharmaceutical Inc

Name	Title
Mr. Vikram Karnani	CEO, President, Executive VP & Director
Ms. Colleen Tupper	Executive VP & CFO
Mr. Scott Dreyer	Executive VP & Chief Commercial Officer
Dr. Thomas B. Smith FAAFP, M.D.	Executive VP & Chief Medical Officer
Mr. David Dieter	Executive VP, General Counsel & Corporate Secretary
Ms. Jane Gonnerman	Executive Vice President of Strategy & Corporate Development
Mr. Dean J. Patras	Chief People Officer
Mr. Scott Sudduth	Head of Technical Operations

Important FAQs about investing in COLL Stock from India :

What is Collegium Pharmaceutical share price today?

Collegium Pharmaceutical share price today is $38.81 as on August 30, 2025 at 1:29 am IST at the close of the market. Collegium Pharmaceutical share today touched a day high of $38.82 and a low of $38.25.

What is the 52 week high and 52 week low for Collegium Pharmaceutical share?

Collegium Pharmaceutical share touched a 52 week high of $42.29 and a 52 week low of $23.23. Collegium Pharmaceutical stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $38.81, lower by 8.22% versus the 52 week high.

How to invest in Collegium Pharmaceutical Stock (COLL) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Collegium Pharmaceutical on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Collegium Pharmaceutical Shares that will get you 0.0386 shares as per Collegium Pharmaceutical share price of $38.81 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Collegium Pharmaceutical Stock (COLL) from India?

Indian investors can start investing in Collegium Pharmaceutical (COLL) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Collegium Pharmaceutical stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Collegium Pharmaceutical share’s latest price of $38.81 as on August 30, 2025 at 1:29 am IST, you will get 0.2577 shares of Collegium Pharmaceutical. Learn more about fractional shares .

What are the returns that Collegium Pharmaceutical has given to Indian investors in the last 5 years?

Collegium Pharmaceutical stock has given 107.46% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?